SYNAGIS (palivizumab) | Parent & Caregiver Website
WEBSYNAGIS is a prescription medication that is injected (50 mg and 100 mg) in certain children to help prevent serious lung disease caused by respiratory syncytial virus (RSV). You should know that SYNAGIS is used to prevent RSV, and not to treat children who already have RSV, including children:
Palivizumab Prophylaxis in Infants and Young Children at …
WEBJun 26, 2023 · The palivizumab package insert states “Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.” 1 In the absence of a specific definition of “high risk” by the FDA, the AAP has endeavored, since palivizumab was first licensed, to provide more precise ...
Palivizumab - Wikipedia
WEBPalivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.
Synagis: Package Insert - Drugs.com
WEBMar 20, 2024 · Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season,
Synagis Vaccine: Uses, Dosage, Side Effects - Drugs.com
WEBDec 27, 2023 · Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease. Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants).
Updated Guidance for Palivizumab Prophylaxis Among Infants and …
WEBAug 1, 2014 · Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection | Pediatrics | American Academy of Pediatrics. From the American Academy of Pediatrics | Policy Statement | August 01 2014.
Synagis | European Medicines Agency
WEBSynagis is used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) that would require hospitalisation. It is used in the following groups of children, who are at high risk for this disease:
Synagis (palivizumab): Uses, Side Effects, FAQs & More - GoodRx
WEBFeb 4, 2024 · Synagis (palivizumab) is a monoclonal antibody. It's given to prevent serious respiratory syncytial virus (RSV) infections in infants and young children who are at high risk for severe illness. Synagis (palivizumab) is injected into the muscle monthly, starting right before and continuing throughout the RSV season.
Synagis Intramuscular: Uses, Side Effects, Interactions ... - WebMD
WEBFind patient medical information for Synagis intramuscular on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
Synagis (Palivizumab) | Treatments | Patients & Families | UW Health
WEBSynagis is a medicine called a monoclonal antibody. Monoclonal antibodies act like your body’s own immune system to help fight off infections. The effects of Synagis last for one month. What is Synagis used for? Synagis is used to prevent severe illness in your child from a virus called respiratory syncytial virus (RSV). What is RSV?
Skip to content